Sponsored by the National Health Commission Training Base for Blindness Prevention and Treatment of Blindness, Beijing Ophthalmology Society and He's Ophthalmology Group, and undertaken by the International Ophthalmologist Training Institute and Beijing He's Eye Hospital, the "Whole Life Cycle Eye Health Promotion Campaign - Fundus Disease Diagnosis and Treatment New Technology Summit Forum" was held in Beijing from December 15th to 16th.
Group photo of experts and scholars participating in this summit forum.
Professor Wei Wenbin, Professor Cao Xusheng, Professor Wang Dongsheng, Professor Liu Yueming, Chief Expert of Fundus Disease of Beijing Tongren Hospital Affiliated to Capital Medical University, Professor Zhao Mingwei of Peking University People's Hospital, Professor Kang Zefeng of China Academy of Chinese Medical Sciences Eye Hospital, Professor Dai Rongping of Beijing, Professor Pang Jijing, Director of the Institute of Clinical Transformation of Gene ** of He Ophthalmology Group, and more than 30 top domestic ophthalmology experts and scholars gathered together, focusing on hereditary retinal diseases, rare fundus diseases, intraocular malignant tumors, macular degeneration, The new technologies, new advances, and latest research results in the diagnosis and treatment of various fundus diseases such as sugar reticulation, uvea, choroid, etc., have been warmly exchanged and deepened, and suggestions have been made to promote the progress and development of the diagnosis and treatment of fundus diseases.
Fundus disease is a kind of eye disease with many kinds of diseases, complex and changeable diseases, its harm to the human body, in addition to affecting visual ability, can cause blindness in serious cases, and has become the first irreversible blinding eye disease in China.
In the early days of its establishment, Ho's Ophthalmology Department carried out retinal laser photocoagulation (i.e., fundus laser technology) and vitrectomy technology for the treatment of vitreoretinal lesions. Since then, micropulse laser technology, anti-VEGF intravitreal injection technology and minimally invasive glass resection and other surgical techniques have been introduced, providing more first-class solutions for patients with vitreoretinal diseases.
In recent years, with the continuous development of precision medicine, Ho's Ophthalmology has also applied gene technology to the detection and diagnosis and treatment of diabetic eye diseases and hereditary retinal diseases.
Professor Pang Jijing, Technical Dean of Shenyang He Eye Hospital.
At this forum, Professor Pang Jijing, Director of the Clinical Translational Institute of Genetics ** of He's Ophthalmology Group, shared the "Genes of Hereditary Retinal Diseases**" and analyzed and shared the efficacy of the first case of congenital amaurosis type 2 in Chinese mainland in which Ho's Ophthalmology participated after using Luxturna gene drugs.
Du Liling, chairman of the conference and president of Beijing He Eye Hospital, delivered a speech.
Du Liling, the chairman of the conference and president of Beijing He Eye Hospital, also shared the practical experience of He's Ophthalmology in providing full life cycle eye health management for people of different ages and with different eye health needs based on digital tools and means. At the same time, she also called on all sectors of society to pay attention to the prevention and treatment of fundus diseases, and work together to build a complete eye health protection system for the whole life cycle.
The successful holding of this summit forum not only provides a platform for ophthalmic practitioners to communicate and learn from Xi, but also injects new impetus into the cause of eye health led by scientific and technological innovation.